Optimeos Life Sciences — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $8M

Overview

Optimeos Life Sciences is a private, preclinical-stage biotech founded in 2020 and based in Cambridge, Massachusetts. The company has developed a versatile nanoparticle delivery platform with two core formulations: CINCs for targeted intracellular delivery of nucleic acids and LINCs for long-acting extracellular delivery of peptides. Its pipeline includes programs in rare liver disease, in vivo T cell engineering, and long-acting GLP-1 for obesity, supported by non-dilutive SBIR grants and active business development efforts. Optimeos is positioned to address significant limitations in non-viral gene therapy and peptide delivery.

Rare DiseasesImmunologyMetabolic Diseases

Technology Platform

Inverse Flash NanoPrecipitation platform creating two formulation types: CINCs (Coated Inverse NanoCarriers) for targeted intracellular delivery of nucleic acids/proteins, and LINCs (Long-acting Inverse NanoCarriers) for sustained extracellular release of peptides/proteins. Key features include multi-payload co-encapsulation, tunable targeting, controlled release, and tunable immunogenicity.

Funding History

1

Total raised:$8M

Seed$8MUndisclosedMay 15, 2021

Opportunities

The platform addresses large markets in non-viral gene therapy and long-acting injectables, where improving targeting and tolerability can create best-in-class therapeutics.

Strategic partnerships with large biopharma companies seeking delivery solutions for their biologic and nucleic acid pipelines offer a near-term value inflection and non-dilutive funding.

Risk Factors

Key risks include the technical challenge of translating sophisticated nanoparticle engineering into safe and effective human therapies, intense competition in the drug delivery space, and reliance on securing partnerships to fund and validate the platform.

As a pre-revenue, preclinical company, it faces significant execution and financing risks.

Competitive Landscape

Optimeos competes in the advanced drug delivery space against numerous biotechs and academic groups developing next-generation lipid nanoparticles, polymer-based carriers, and other non-viral delivery technologies. Its differentiation lies in the specific Inverse Flash NanoPrecipitation process, claims of superior multi-payload capacity and targeting, and its dual focus on intracellular nucleic acid delivery and long-acting peptide depots.

More companies in Drug Delivery & Formulation →More companies in United States →